Peptides DB
Research-centric peptide and protocol reference hub

NAD+ (Nicotinamide Adenine Dinucleotide) record · updated 20h ago

Metabolic & appetiteNeuro & moodGrade A · human clinicalResearch use only
All 31 studiesJump to the evidenceCompare
What is NAD+ (Nicotinamide Adenine Dinucleotide) used for?

NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.

How it works: Coenzyme in redox reactions

Primarily researched for · Metabolic & appetiteRoute · Intravenous infusion

Development stage

where NAD+ (Nicotinamide Adenine Dinucleotide) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Current
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 114 registered trials. It describes the research record, not a recommendation.

Identity
NameNAD+ (Nicotinamide Adenine Dinucleotide)
Chain length—
Molecular weight663.4 Da
FormulaC21H27N7O14P2
Structure typeNot established
ClassMetabolic
Research levelModerate Research
Discovered byCurated master list · 2025

Mass and formula from PubChem CID 5892. No verified residue count for this compound.

Pharmacology
MechanismCoenzyme in redox reactions
RouteIntravenous infusion
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 24, 2026. How this works →
Research stats
Total studies31
Human / animal / cellular5 / 10 / 8
Highest trial phasePhase 1
Years covered2010–2026
Latest study2d ago
Publication history
20102026
Research funding
4,207 NIH projects · $22.1M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports5
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

31 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Mitogenomic characterisation of non-native freshwater snails in Australia: Implications for biosecurity and trematode vector surveillance.
FindingGenome sizes ranged from 13.7 to 14.3 kb.
Animal2026Full text read0.80
Unlocking the healing power of Berberine: A promising aid for multiple sclerosis.
FindingNot reported in abstract.
review2026Full text read0.80
Efficacy of tannins as silage additives to inhibit deamination process during ensiling: a meta-analysis and <i>in silico</i> approach.
FindingTannin supplementation significantly reduced NH₃-N, NPN, and soluble nitrogen concentrations (p < 0.001).
review2026Full text read0.80
Evaluation of the safety and potential genotoxicity of a high-purity mogroside ingredient containing siamenoside I produced from a modified strain of &lt;i&gt;Yarrowia lipolytica&lt;/i&gt;.
FindingNOAEL of 50,000 ppm in male rats (3309 mg/kg-bw/day) and female rats (3362 mg/kg-bw/day) in 90-day study.
In vitro2026Full text read0.80
Evolution of alcohol oxidase for improved methanol bioconversion and formaldehyde tolerance.
FindingSixfold increase in catalytic efficiency (7.7 s^-1 mM^-1).
In vitro2026Full text read0.80
Improved catalytic efficiency of P450 OleP for converting lithocholic acid into murideoxycholic and ursodeoxycholic acids through semi-rational and rational design.
FindingMDCA conversion rate improved from 32.5% to 98.3% with S240A mutant.
In vitro2026Full text read0.80
Complete POR ablation in human adrenal cells reveals steroidogenic rerouting and variant-dependent loss of cytochrome P450 support
FindingNot reported in abstract.
In vitro2026Full text read0.80
Transancestral TWAS Enrichment of NMN- Informed Pathways in Type 2 Diabetes: CPT2- Linked Fatty-Acid Oxidation and MAP2K1/MAPK3 Drivers as Translational Bridges
FindingStouffer Z = −9.70 for fatty-acid-degradation association in the European group, permutation p = 0.0077.
review2026Full text read0.80
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD(+) to eradicate KRAS-driven AML.
TakeawayNot reported in abstract.
—2026Title only0.10
NAD-dependent redox control enables endothelial quiescence and vascular stabilization during angiogenesis.
TakeawayNot reported in abstract.
—2026Title only0.10
Metabolite-specific Reproducibility of Cerebral <sup>31</sup> P-MRS at 3T: Recommendations for Clinical Research
FindingTest-retest variability ranged from ∼5-25 CoV%, n=Not reported in abstract.
Human2026Full text read0.70
Aging disrupts cumulus-oocyte NAD homeostasis
FindingNot reported in abstract.
Animal2023Partial text0.50

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching NAD+ (Nicotinamide Adenine Dinucleotide) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much NAD+ (Nicotinamide Adenine Dinucleotide) is discussed should be drawn from it.

Articles mentioning NAD+ (Nicotinamide Adenine Dinucleotide)